METHODS FOR PREDICTING THE RESPONSE OF A PATIENT TO TREATMENT WITH A PD-1 OR PD-L1 IMMUNE CHECKPOINT INHIBITOR

The present invention provides methods for predicting the response of a patient in need of an immune checkpoint inhibitor (ICI), to treatment with a programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) ICI, comprising the steps of: (a) measuring the kinase activity of at least two kinases independently selected from within at least two families of kinases selected from the group consisting of: the VEGFR or PDGFR family of kinases; the SRC family of kinases; the SYK family of kinases; the TAM family of kinases; the JakA family of kinases; and the ALK family of kinases, in a blood sample obtained from said patient, thereby providing a kinase activity profile of said blood sample; and (b) predicting from said kinase activity profile the response of said patient to treatment with said PD-1 or PD-L1 ICI, and kits for predicting the response of a patient in need of an ICI to treatment with a PD-1 or PD-L1 ICI.